June brought major blood cancer updates, and CURE is sharing the latest in myelofibrosis treatment and FDA breakthroughs, as ...

The VERIFY trial explores rusfertide to manage polycythemia vera without causing iron deficiency symptoms, Dr. Aaron Gerds ...

During a live event, Mojtaba Akhtari, MD, discussed the goals and treatment approach for patients with low-risk polycythemia ...

Merck's growing pipeline, with nearly 20 new launches ahead, is set to reshape its portfolio as Keytruda's 2028 patent expiry ...

Early results from the phase 1 SANRECO trial suggest that divesiran is safe and well tolerated, and may reduce the need for phlebotomy in patients with polycythemia vera by increasing hepcidin levels ...

Silence Therapeutics presents additional data from phase 1 study of divesiran as potential first-in-class siRNA treatment for polycythemia vera: London Monday, June 16, 2025, 18:0 ...

Panelists discuss how to select among the four available JAK inhibitors (Ruxolitinib, Fedratinib, Pacritinib, and Momelotinib) based on patient-specific factors such as anemia, thrombocytopenia, and ...

CURRENTLY, polycythemia vera is considered by most hematologists to fall in the category of myeloproliferative disorders, ... erythremic myelosis, myelofibrosis, ...

Polycythemia vera is a myeloproliferative neoplasm in which the bone marrow produces too ... and mean changes from baseline in PROMIS Fatigue SF-8a score and Myelofibrosis Symptom Assessment ...

Incyte INCY announced that the FDA has extended the review period for the supplemental new drug application (sNDA) for ...

Polycythemia Vera Pipeline . Polycythemia Vera Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non ...

DataM Intelligence | competitive Intelligence JAK combos, epigenetic drugs, & non-JAK agents are redefining myelofibrosis treatment offerin ...